iodixanol and via 2291

iodixanol has been researched along with via 2291 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brotz, TM; Cossette, M; Grégoire, JC; Ibrahim, R; Kouz, S; L'allier, PL; Lavoie, MA; Nozza, A; Paquin, J; Pressacco, J; Tardif, JC; Taub, R	1

Trials

1 trial(s) available for iodixanol and via 2291

Article	Year
Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circulation. Cardiovascular imaging, 2010, Volume: 3, Issue:3 Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Analysis of Variance; Arachidonate 5-Lipoxygenase; Biomarkers; C-Reactive Protein; Contrast Media; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxyurea; Leukotriene B4; Leukotriene E4; Lipoxygenase Inhibitors; Male; Middle Aged; Observer Variation; Prospective Studies; Radiographic Image Enhancement; Tomography, X-Ray Computed; Treatment Outcome; Triiodobenzoic Acids	2010

Article

Year

Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome.

Circulation. Cardiovascular imaging, 2010, Volume: 3, Issue:3

Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Analysis of Variance; Arachidonate 5-Lipoxygenase; Biomarkers; C-Reactive Protein; Contrast Media; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxyurea; Leukotriene B4; Leukotriene E4; Lipoxygenase Inhibitors; Male; Middle Aged; Observer Variation; Prospective Studies; Radiographic Image Enhancement; Tomography, X-Ray Computed; Treatment Outcome; Triiodobenzoic Acids

2010